Literature DB >> 25696888

Reproductive issues in sickle cell disease.

Kim Smith-Whitley1.   

Abstract

As medical advances improve survival, reduce disease-related morbidity, and improve quality of life, reproductive issues will take higher priority in the sickle cell disease (SCD) community. A wide variety of topics are addressed in this chapter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD. Etiologies of impaired male fertility are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complications of medical therapies. Much less is known about the prevalence and etiology of infertility in women with SCD. Other reproductive issues in women included in this review are pain and the menstrual cycle, contraception, and preconception counseling. Finally, long-term therapies for SCD and their impact on fertility are presented. Transfusional iron overload and gonadal failure are addressed, followed by options for fertility preservation after stem cell transplantation. Focus is placed on hydroxyurea therapy given its benefits and increasing use in SCD. The impact of this agent on spermatogenesis, azoospermia, and the developing fetus is discussed.
© 2014 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25696888     DOI: 10.1182/asheducation-2014.1.418

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  10 in total

Review 1.  Abnormal Uterine Bleeding in Young Women with Blood Disorders.

Authors:  Kathryn E Dickerson; Neethu M Menon; Ayesha Zia
Journal:  Pediatr Clin North Am       Date:  2018-06       Impact factor: 3.278

Review 2.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 3.  Fertility counseling and preservation: considerations for the pediatric endocrinologist.

Authors:  Amanda J Saraf; Leena Nahata
Journal:  Transl Pediatr       Date:  2017-10

Review 4.  Sexual dysfunction and male infertility.

Authors:  Francesco Lotti; Mario Maggi
Journal:  Nat Rev Urol       Date:  2018-03-13       Impact factor: 14.432

Review 5.  Indications for transfusion in the management of sickle cell disease.

Authors:  Hyojeong Han; Lisa Hensch; Venée N Tubman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

7.  Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement.

Authors:  Traci M Kazmerski; Elizabeth Miller; Gregory S Sawicki; Phaedra Thomas; Olga Prushinskaya; Eliza Nelson; Kelsey Hill; Anna Miller; S Jean Emans
Journal:  Patient       Date:  2019-04       Impact factor: 3.883

8.  Consequences of β-Thalassemia or Sickle Cell Disease for Ovarian Follicle Number and Morphology in Girls Who Had Ovarian Tissue Cryopreserved.

Authors:  Linn Salto Mamsen; Stine Gry Kristensen; Susanne Elisabeth Pors; Jane Alrø Bøtkjær; Erik Ernst; Kirsten Tryde Macklon; Debra Gook; Ajay Kumar; Bhanu Kalra; Claus Yding Andersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-15       Impact factor: 5.555

9.  Life-Threatening Acute Chest Syndrome in a Patient With Sickle Cell Disease After Switching From Hydroxyurea Therapy to Partial Exchange Transfusions: A Case Report.

Authors:  Ann K Kvam; Henrik A Torp; Per O Iversen
Journal:  Cureus       Date:  2021-12-07

10.  Ovarian reserve in nigerian women with sickle cell anaemia: a cross- sectional study.

Authors:  Sunusi Rimi Garba; Christian Chigozie Makwe; Vincent Oluseye Osunkalu; Olufunto Olufela Kalejaiye; Adaiah Priscillia Soibi-Harry; Amina Umar Aliyu; Bosede Bukola Afolabi
Journal:  J Ovarian Res       Date:  2021-12-11       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.